Healthcare / Drug Manufacturers - Specialty & GenericNSE
$860.80
+4.20 (+0.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-1.1B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$49.3B
P/E
34.9x
↑EV/EBITDA
21.0x
↑ROE
12.9%
↑Gross Margin
35.4%
↓Debt/Equity
0.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+20.8%
FCF CAGR
—
FCF margin
3.0%
FCF / Net income
0.34x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $16.30B · net income $1.41B · FCF $481.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $16.30B | $16.30B | $12.44B | $10.77B | $9.25B |
| Net Income | $1.41B | $1.41B | $1.28B | $943.5M | $679.5M |
| EBITDA | $2.50B | $2.50B | $1.98B | $1.67B | $1.22B |
| EPS | 24.63 | 24.63 | 22.41 | 18.66 | 11.87 |
| Gross Margin | 35.4% | 35.4% | 34.5% | 30.3% | 24.2% |
| Operating Margin | 12.1% | 12.1% | 13.0% | 13.1% | 11.4% |
| Net Margin | 8.6% | 8.6% | 10.3% | 8.8% | 7.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.32 | 0.32 | 0.35 | 0.29 | 0.86 |
| Current Ratio | 1.87 | 1.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $481.6M | $481.6M | $-1.09B | $-1.41B | $-118.7M |
| Returns | |||||
| ROE | 12.9% | 12.9% | 13.4% | 11.4% | 24.6% |
| Valuation | |||||
| P/E | 34.91 | 34.91 | 38.88 | 24.87 | — |
| EV/EBITDA | 21.03 | 21.03 | 26.79 | 15.48 | — |
| P/B | 4.52 | 4.52 | 5.20 | 2.82 | — |
| Growth & Yield | |||||
| Revenue Growth | 31.1% | 31.1% | 15.5% | 16.4% | — |
| EPS Growth | 9.9% | 9.9% | 20.1% | 57.1% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
45.8%
EPS terminal req.
$76.38
Spread vs growth
-35.9%
5Y implied EPS CAGR
30.3%
EPS terminal req.
$92.42
Spread vs growth
-20.4%
10Y implied EPS CAGR
19.7%
EPS terminal req.
$148.85
Spread vs growth
-9.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.0%
Start / end P/E
39.7x → 34.5x
EPS bridge
22.41 → 24.63
Residual
-1.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.